OTCMKTS:BNKL

Bionik Laboratories Stock Forecast, Price & News

$1.74

0.00 (0.00 %)

(As of 08/2/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.74

▼

$1.74

50-Day Range

$1.50

▼

$2.86

52-Week Range

$0.75

▼

$4.50

VolumeN/A

Average Volume561 shs

Market Capitalization$8.71 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.57

30 days | 90 days | 365 days | Advanced Chart

Receive BNKL News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionik Laboratories and its competitors with MarketBeat's FREE daily newsletter.

About Bionik Laboratories

Bionik Laboratories Corp. engages in the provision of rehabilitation and mobility solutions to individuals with neurological disorders. Its products include InMotion ARM, InMotion HAND, and InMotion WRIST. The company was founded by Michal Prywata and Thiago Caires on January 8, 2010 and is headquartered in Toronto, Canada.

BIONIK Laboratories Announces $5 Million Capital Raise through Issuance of Convertible Notes
July 29, 2021 | finance.yahoo.com

Bionik Laboratories (OTCMKTS:BNKL) Trading Up 58.9%
July 13, 2021 | americanbankingnews.com

BIONIK Laboratories Reports Fiscal 2021 Q3 Financial Results
February 11, 2021 | finance.yahoo.com

BIONIK Laboratories Corp. Appoints Rich Russo, Jr. as CFO
November 30, 2020 | finance.yahoo.com

BIONIK Laboratories Announces Fiscal 2021 Q2 Financial Results
November 12, 2020 | finance.yahoo.com

BIONIK Laboratories Announces Sale of New InMotion® ARM/HAND Robotic Device to VA Rehabilitation Research & Development’s Center for Neurorestoration and Neurotechnology
October 9, 2020 | finance.yahoo.com

Bionik Laboratories Corp. Appoints Dr. Eric Dusseux as Chief Executive Officer
September 29, 2020 | bloomberg.com

BIONIK Laboratories Announces Fiscal 2021 Q1 Financial Results
August 13, 2020 | finance.yahoo.com

BIONIK Laboratories Announces Fiscal 2020 Financial Results
June 30, 2020 | finance.yahoo.com

BIONIK Laboratories Launches InMotion Connect™, Driving Outcomes through Internet of Things (IoT) and Intelligent Data
June 25, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BNKL
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.bioniklabs.com
Phone(416) 640-7887
Employees19
Year FoundedN/A

Sales & Book Value

Annual Sales$1.19 million
Price / Sales7.32
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.66 per share
Price / Book2.64

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares5,005,000
Market Cap$8.71 million
Next Earnings Date8/12/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.21 out of 5 stars

Medical Sector

1309th out of 2,226 stocks

Surgical Appliances & Supplies Industry

30th out of 41 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Bionik Laboratories.

4.4 Community Rank

Outperform Votes
Bionik Laboratories has received 103 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bionik Laboratories has received 51 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bionik Laboratories has received 66.88% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bionik Laboratories and other stocks. Vote “Outperform” if you believe BNKL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BNKL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Bionik Laboratories does not currently pay a dividend.
Dividend Growth
Bionik Laboratories does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bionik Laboratories insiders have not sold or bought any company stock.
Percentage Held by Insiders
36.84% of the stock of Bionik Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Bionik Laboratories is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bionik Laboratories is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bionik Laboratories has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Bionik Laboratories (OTCMKTS:BNKL) Frequently Asked Questions

What stocks does MarketBeat like better than Bionik Laboratories?

Wall Street analysts have given Bionik Laboratories a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bionik Laboratories wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bionik Laboratories' next earnings date?

Bionik Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Bionik Laboratories.

How has Bionik Laboratories' stock price been impacted by COVID-19 (Coronavirus)?

Bionik Laboratories' stock was trading at $1.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BNKL stock has decreased by 0.6% and is now trading at $1.74.
View which stocks have been most impacted by COVID-19.

Who are Bionik Laboratories' key executives?

Bionik Laboratories' management team includes the following people:

Rich Russo, Chief Executive & Financial Officer
Loren W. Wass, Chief Commercial Officer

Who are some of Bionik Laboratories' key competitors?

Some companies that are related to Bionik Laboratories include Advanced Biomedical Technologies (ABMT), Avitar (AVTI), Ortho Regenerative Technologies (ORTIF), Pathfinder Cell Therapy (PFND) and PC Group (PCGR).
View all of BNKL's competitors.

What other stocks do shareholders of Bionik Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bionik Laboratories investors own include Co-Diagnostics (CODX), iBio (IBIO), PerkinElmer (PKI), PharmaCyte Biotech (PMCB), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), Ascent Solar Technologies (ASTI), BioRestorative Therapies (BRTX) and Digital Ally (DGLY).

What is Bionik Laboratories' stock symbol?

Bionik Laboratories trades on the OTCMKTS under the ticker symbol "BNKL."

How do I buy shares of Bionik Laboratories?

Shares of BNKL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bionik Laboratories' stock price today?

One share of BNKL stock can currently be purchased for approximately $1.74.

How much money does Bionik Laboratories make?

Bionik Laboratories has a market capitalization of $8.71 million and generates $1.19 million in revenue each year.

How many employees does Bionik Laboratories have?

Bionik Laboratories employs 19 workers across the globe.

What is Bionik Laboratories' official website?

The official website for Bionik Laboratories is www.bioniklabs.com.

Where are Bionik Laboratories' headquarters?

Bionik Laboratories is headquartered at 483 Bay Street N105, Toronto A6, M5G2C9.

How can I contact Bionik Laboratories?

Bionik Laboratories' mailing address is 483 Bay Street N105, Toronto A6, M5G2C9. The company can be reached via phone at (416) 640-7887 or via email at [email protected]

This page was last updated on 8/2/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here